{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:03:13Z","timestamp":1792159393720,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ophtha.2026.02.013","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:14:35Z","timestamp":1771028075000},"page":"799-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5970","authenticated-orcid":false,"given":"Abdelaziz","family":"Abdelaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem","family":"Abu Serhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Yaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Gaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-375X","authenticated-orcid":false,"given":"Abdelrahman M.","family":"Elhusseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.02.013_bib1","first-page":"1","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2026.02.013_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.02.013_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-025-04031-z","article-title":"Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data","volume":"23","author":"Massy","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2026.02.013_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12886-025-04096-7","article-title":"Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bjophthalmol-2017-311140","article-title":"Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study","volume":"102","author":"Lee","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib7","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ophtha.2026.02.013_bib8","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.02.013_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41433-023-02716-4","article-title":"NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies","volume":"38","author":"Martin-Gutierrez","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2026.02.013_bib10","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0161-6420(00)00258-X","article-title":"Prothrombotic and vascular risk factors in NAION","volume":"107","author":"Egan","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.02.013_bib11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib12","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.02.013_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.02.013_bib17","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2026.02.013_bib18","article-title":"Newcastle-Ottawa quality assessment scale cohort studies","volume":"2014","author":"Wells","year":"2014","journal-title":"Univ Ottawa"},{"key":"10.1016\/j.ophtha.2026.02.013_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib20","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/sim.3602","article-title":"Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses","volume":"29","author":"Jackson","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2026.02.013_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f7450","article-title":"Converting an odds ratio to a range of plausible relative risks for better communication of research findings","volume":"348","author":"Grant","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2026.02.013_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.ophtha.2026.02.013_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2026.02.013_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE working group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system\u2013A disproportionality analysis","volume":"19","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2026.02.013_bib27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?","volume":"19","author":"Procacci","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2026.02.013_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ophtha.2026.02.013_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2026.02.013_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jamaophthalmol.2025.2332","article-title":"GLP-1RA exposure and nonarteritic anterior ischemic optic neuropathy prevalence by diabetes status","volume":"143","author":"Nagdeve","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.04.022","article-title":"Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review","volume":"87","author":"Streeter","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ophtha.2026.02.013_bib35","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","article-title":"Adipose tissue dysfunction in obesity, diabetes, and vascular diseases","volume":"29","author":"Hajer","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ophtha.2026.02.013_bib36","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/HJH.0000000000001731","volume":"36","author":"Kotsis","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.ophtha.2026.02.013_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/aos.17473","article-title":"Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association","volume":"103","author":"Amini","year":"2025","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.ophtha.2026.02.013_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247126","article-title":"Risk factors and visual outcome of non-arteritic ischemic optic neuropathy (NAION): experience of a tertiary center in Kuwait","volume":"16","author":"Behbehani","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2026.02.013_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026000825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026000825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:46:09Z","timestamp":1779263169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026000825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0161642026000825"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}